Skip to main content
SpringerLink
Log in

Amphotericin B

  • Chapter
  • First Online:
Essentials of Clinical Mycology

Abstract

Amphotericin B (AmB) has been the cornerstone of antifungal therapy for almost 50 years. Discovered in the late 1950s, it was approved for human use as an antifungal agent in 1960. Initial formulations of AmB were plagued with impurities. Allergic responses, presumably secondary to these impurities, and endotoxin-like infusion-related reactions were common. Although improvements in purification and fermentation over the last 30 years have enhanced tolerability, infusion-related reactions and renal dysfunction are still commonplace with the use of the deoxycholate solubilized formulation. Formulations using a lipid carrier have significantly improved tolerability. Safety aside, AmB remains the most effective, broad-spectrum, fungicidal agent with the greatest experience for the treatment of systemic mycoses. Both intrinsic and acquired resistance are limited. The treatment failures seen with AmB are multifaceted. These can be attributed to delays in diagnosis of invasive mycoses, the immune compromised state of the patient being treated, the unique pharmacokinetic/pharmacodynamic properties of the different formulations, and dose limitations related to toxicity. In an effort to enhance antifungal efficacy and reduce toxicity, AmB has been combined with other antifungals and new nonlipid formulations are being evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schmitt HJ. New methods of delivery of amphotericin B. Clin Infect Dis. 1993;17 Suppl 2:S501–6.

    PubMed  Google Scholar 

  2. Wasan EK, Bartlett K, Gershkovich P, et al. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm. 2009;372:76–84.

    Article  CAS  PubMed  Google Scholar 

  3. Fukui H, Koike T, Saheki A, Sonoke S, Tomii Y, Seki J. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS). Int J Pharm. 2003;263:51–60.

    Article  CAS  PubMed  Google Scholar 

  4. Cleary JD, Chapman SW, Swiatlo E, Kramer R. High purity amphotericin B. J Antimicrob Chemother. 2007;60(6): 1331–40.

    Article  CAS  PubMed  Google Scholar 

  5. Monforte V, Ussetti P, López R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transpl. 2009; 28:170–5.

    Article  Google Scholar 

  6. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308–29.

    CAS  PubMed  Google Scholar 

  7. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 1990;34:183–8.

    CAS  PubMed  Google Scholar 

  8. Abu-Salah KM. Amphotericin B: An update. Br J Biomed Sci. 1996;53:122–33.

    CAS  PubMed  Google Scholar 

  9. Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis. 1986;154:76–83.

    CAS  PubMed  Google Scholar 

  10. Sandhu DK. Effect of amphotericin B on the metabolism of Aspergillus fumigatus. Mycopathologia. 1979;68:23–9.

    Article  CAS  PubMed  Google Scholar 

  11. Bistoni F, Vecchiarelli A, Mazzolla R, Puccetti P, Marconi P, Garaci E. Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother. 1985;27:625–31.

    CAS  PubMed  Google Scholar 

  12. Lin H, Medoff G, Kobayashi GS. Effects of amphotericin B on macrophages and their precursor cells. Antimicrob Agents Chemother. 1977;11:154–60.

    CAS  PubMed  Google Scholar 

  13. Mozaffarian N, Berman JW, Casadevall A. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother. 1997;41:1825–9.

    CAS  PubMed  Google Scholar 

  14. Rogers PD, Jenkins JK, Chapman SW, Ndebele K, Chapman BA, Cleary JD. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis. 1998;178:1726–33.

    Article  CAS  PubMed  Google Scholar 

  15. Cenci E, Mencacci A, Del Sero G, Bistoni F, Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis. 1997;176:217–26.

    Article  CAS  PubMed  Google Scholar 

  16. Marmer DJ, Fields BT, France GL, Steele RW. Ketoconazole, amphotericin B, and amphotericin B methyl ester: Comparative in vitro and in vivo toxicological effects on neutrophil function. Antimicrob Agents Chemother. 1981;20:660–5.

    CAS  PubMed  Google Scholar 

  17. Nair MPN, Schwartz SA. Immunomodulatory effects of ampho­tericin-B on cellular cytotoxicity of normal human lymphocytes. Cell Immunol. 1982;70:287–300.

    Article  CAS  PubMed  Google Scholar 

  18. Stewart SJ, Spagnuolo PJ, Ellner JJ. Generation of suppressor T lymphocytes and monocytes by amphotericin B. J Immunol. 1981;127:135–9.

    CAS  PubMed  Google Scholar 

  19. Speeleveld E, Gordts B, Van Landuyt HW, De Vroey C, Raes-Wuytack C. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses. 1996;39:37–40.

    Article  CAS  PubMed  Google Scholar 

  20. Powderly WG, Keath EJ, Sokol-Anderson M, Robinson K, Kitzd, Little JR. Amphotericin B resistant Cryptococcus neoformans in a patient with AIDS. Infect Dis Clin Pract. 1992;1:314–6.

    Google Scholar 

  21. Le TP, Tuazoncu CU, Levine M, Borum M, Rollhauser C. Resistance to fluconazole and amphotericin B in patients with AIDS who are being treated for candidal esophagitis. Clin Infect Dis. 1996;23:649–50.

    CAS  PubMed  Google Scholar 

  22. Kelly SL, Lamb DC, Kelly DE, et al. Resistance to fluconazole and cross resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta 5, 6-desaturation. FEBS Lett. 1997;400:80–2.

    Article  CAS  PubMed  Google Scholar 

  23. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52:197–205.

    Article  PubMed  Google Scholar 

  24. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic stratagies. Antimicrob Agents Chemother. 1996;40:279–91.

    CAS  PubMed  Google Scholar 

  25. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501–17.

    CAS  PubMed  Google Scholar 

  26. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother. 2006;50:1287–92.

    Article  CAS  PubMed  Google Scholar 

  27. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition. Document M27-A3. Wayne: Clinical and Laboratory Standards Institute, 2008

    Google Scholar 

  28. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard CLSI document M38-A. Wayne: Clinical Laboratory Standards Institute, 2001.

    Google Scholar 

  29. Larsen RA, Bauer M, Brouwer AE, et al. In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob Agents Chemother. 2007;51:343–5.

    Article  CAS  PubMed  Google Scholar 

  30. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989;33:362–8.

    CAS  PubMed  Google Scholar 

  31. Christiansen KJ, Bernard EM, Gold JWM, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985;152:1037–43.

    CAS  PubMed  Google Scholar 

  32. van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of criticlly ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59:952–6.

    Article  PubMed  CAS  Google Scholar 

  33. Atkinson Jr AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother. 1978;13:271–6.

    PubMed  Google Scholar 

  34. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet. 1983;8:17–42.

    Article  CAS  PubMed  Google Scholar 

  35. Gussak HM, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis. Am J Kidney Dis. 2001;37:E45.

    Article  CAS  PubMed  Google Scholar 

  36. Starke JR, Mason Jr EO, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987;155:766–74.

    CAS  PubMed  Google Scholar 

  37. Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother. 1989;33:1989–93.

    CAS  PubMed  Google Scholar 

  38. Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy. 2001;21:302S–18.

    Article  CAS  PubMed  Google Scholar 

  39. Andes D, Stamsted T, Conklin R. Pharmacodynamics of ampho­tericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001;45(3):922–6.

    Article  CAS  PubMed  Google Scholar 

  40. Turnidge JD, Gudmondsson S, Vogelman B, Craig WA. The postantibiotic effect of antifungal agents against common pathogenic yeast. J Antimicrob Chemother. 1994;34:83–92.

    Article  CAS  PubMed  Google Scholar 

  41. Ernst E, Klepser ME, Pfaller MA. Post-antifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000;44:1108–11.

    Article  CAS  PubMed  Google Scholar 

  42. Drutz DJ, Spickard A, Rogers DE, Koenig MG. Treatment of disseminated mycotic infections. A new approach to amphotericin B therapy. Am J Med. 1968;5:405–18.

    Article  Google Scholar 

  43. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182:274–82.

    Article  CAS  PubMed  Google Scholar 

  44. Andreoli TE. On the anatomy of amphotericin B-cholesterol pores in lipid bilayer membranes. Kidney Int. 1973;4:337–45.

    Article  CAS  PubMed  Google Scholar 

  45. Hsuchen CC, Feingold DS. Selective membrane toxicity of the polyene antibiotics: studies on natural membranes. Antimicrob Agents Chemother. 1973;4:316–9.

    CAS  PubMed  Google Scholar 

  46. Cleary JD, Chapman SW, Nolan RL. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother. 1992;36:977–81.

    CAS  PubMed  Google Scholar 

  47. Rogers PD, Stiles JK, Chapman SW, Cleary JD. Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. J Infect Dis. 2000;182:1280–3.

    Article  CAS  PubMed  Google Scholar 

  48. Rogers PD, Perason MM, Cleary JD, Chapman SW, Sullivan DC. Differential expression of genes encoding for immunodulatory proteins in response to amphotericin B in the human monocytic cell line THP-1 identified by cDNA array analysis. J Antimicrob Chemother. 2002;50:811–7.

    Article  CAS  PubMed  Google Scholar 

  49. Cleary JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp T. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother. 1993;27:715–8.

    CAS  PubMed  Google Scholar 

  50. Lin AC, Goldwasser E, Bernard EM, Chapman SW. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis. 1990;161:348–51.

    CAS  PubMed  Google Scholar 

  51. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf. 1990;5:94–108.

    Article  CAS  PubMed  Google Scholar 

  52. Carlson MA, Condon RE. Nephrotoxicity of amphotericin B. J Am Coll Surg. 1994;179:361–81.

    CAS  PubMed  Google Scholar 

  53. Butler WT, Bennett JE, Alling DW, Wertlake PT, Utz JP, Hill G. Nephrotoxicity of amphotericin B. Early and late effects in 81 patients. Ann Intern Med. 1964;61:175–87.

    CAS  PubMed  Google Scholar 

  54. Sawaya BP, Weihprech TH, Campbell WR, et al. Direct basal vasoconstriction as a possible cause for amphotericin B nephrotoxicity in rats. J Clin Inves. 1991;87:2097–107.

    Article  CAS  Google Scholar 

  55. Cheng JT, Witty RT, Robinson RR, Yarger WE. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int. 1982;22:626–33.

    Article  CAS  PubMed  Google Scholar 

  56. Branch RA, Jackson EK, Jacqz E, et al. Amphotericin B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr. 1987;65:500–6.

    Article  CAS  PubMed  Google Scholar 

  57. Branch RA. Prevention of amphotericin B-induced renal impairment: a review of the use of sodium supplementation. Arch Intern Med. 1988;148:2389–94.

    Article  CAS  PubMed  Google Scholar 

  58. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis. 1995;20:755–61.

    CAS  PubMed  Google Scholar 

  59. North RJ. The action of cortisone acetate on cell-mediated immunity to infection: Suppression of host cell proliferation and alteration of cellular composition of infective foci. J Exp Med. 1971;134:1485–500.

    Article  CAS  PubMed  Google Scholar 

  60. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol. 1982;129:1803–5.

    CAS  PubMed  Google Scholar 

  61. Burks LC, Aisner J, Fortner CL, Wiernik PH. Meperidine for the treatment of shaking chills and fever. Arch Intern Med. 1980;140:483–4.

    Article  CAS  PubMed  Google Scholar 

  62. Antoniskis D, Larsen RA. Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother. 1990;34:470–2.

    CAS  PubMed  Google Scholar 

  63. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combination use of ampho­tericin B and leukcocyte transfusions. N Engl J Med. 1981;304:1185–9.

    Article  CAS  PubMed  Google Scholar 

  64. Dutcher JP, Kendall J, Norris D, Schiffer C, Aisner J, Wiernik PH. Granulocyte transfusion therapy and amphotericin B adverse reactions. Am J Hematol. 1989;31:102–8.

    Article  CAS  PubMed  Google Scholar 

  65. Present CA, Klahr C, Santala R. Amphotericin B induction of sensitivity to adriamycin, 1, 3-bis (2-chloroethyl)-1 nitrosourea (BCNU) plus cyclophosphamide in human neoplasia. Ann Intern Med. 1977;86:47–9.

    Google Scholar 

  66. Medoff G. Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. Rev Infect Dis. 1987;9:403–7.

    CAS  PubMed  Google Scholar 

  67. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis. 1998;26:1266–9.

    Article  CAS  PubMed  Google Scholar 

  68. Sugar AM. Use of amphotericin B with azoles with antifungal drugs: what are we doing? Antimicrob Agents Chemother. 1995;39:1907–12.

    CAS  PubMed  Google Scholar 

  69. Peacock Jr JE, Herrington DA, Cruz JM. Amphotericin B therapy: past, present, future. Infect Dis Clin Pract. 1993;2:81–93.

    Article  Google Scholar 

  70. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221–8.

    Article  CAS  PubMed  Google Scholar 

  71. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979;301:126–31.

    Article  CAS  PubMed  Google Scholar 

  72. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987;317:334–41.

    Article  CAS  PubMed  Google Scholar 

  73. Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15–21.

    Article  PubMed  Google Scholar 

  74. Lewis RE, Kontoyiannis P. Rationale for combination antifungal therapy. Pharmacotherapy. 2001;21:149S–64.

    Article  CAS  PubMed  Google Scholar 

  75. Griswold MW, Briceland LL, Stein DS. Is amphotericin B test dosing needed? Ann Pharmacother. 1998;32:475–7.

    Article  CAS  PubMed  Google Scholar 

  76. Cleary JD, Weisdorf D, Fletcher CV. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm. 1988;22:769–72.

    CAS  PubMed  Google Scholar 

  77. Craven PC, Gremillion DH. Risk factors for ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother. 1985;27:868–71.

    CAS  PubMed  Google Scholar 

  78. Bowler WA, Weiss PJ, Hill HE, et al. Risk of ventricular dysrythmias during one hour infusions of amphotericin B in patients with preserved renal function. Antimicrob Agents Chemother. 1992;36:2542–3.

    CAS  PubMed  Google Scholar 

  79. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. Br Med J. 2001;322:579–82.

    Article  CAS  Google Scholar 

  80. Wen DY, Bottini AG, Hall WA, Haines SJ. Infections in neurologic surgery. The intraventricular use of antibiotics. Neurosurg Clin N Am. 1992;3:343–54.

    CAS  PubMed  Google Scholar 

  81. Lesar TS, Fiscella RG. Antimicrobial drug delivery to the eye. Drug Intell Clin Pharm. 1985;19:642–54.

    CAS  PubMed  Google Scholar 

  82. Piraino B, Bailie GR, Bernardini J, et al. ISPD guidelines/recommendations. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int. 2005;25:107–31.

    PubMed  Google Scholar 

  83. Fan-Havard P, Odonovan C, Smith SM, Oh J, Bamberger M, Eng RHK. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis. 1995; 21:960–5.

    CAS  PubMed  Google Scholar 

  84. O’Riordan T, Faris M. Inhaled antimicrobial therapy. Respir Care Clin N Am. 1999;5:617–31.

    PubMed  Google Scholar 

  85. Diot P, Dequin PF, Rivoire B, et al. Aerosols and anti-infectious agents. J Aerosol Med. 2001;14:55–64.

    Article  CAS  PubMed  Google Scholar 

  86. King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. Clin Infect Dis. 1998;27:1151–60.

    Article  CAS  PubMed  Google Scholar 

  87. Sobel JD. Use of antifungal drugs in pregnancy: a focus on safety. Drug Saf. 2000;23:77–85.

    Article  CAS  PubMed  Google Scholar 

  88. Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidemia in neutropenic patients. J Antimicrob Chemother. 1993;31:161–9.

    Article  CAS  PubMed  Google Scholar 

  89. Ayestaran A, Lopez RM, Montoro JB, et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob Agents Chemother. 1996;40:609–12.

    CAS  PubMed  Google Scholar 

  90. Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother. 1996;30:409–12.

    CAS  PubMed  Google Scholar 

  91. Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy. 1999;19:306–23.

    Article  CAS  PubMed  Google Scholar 

  92. Janknergt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet. 1992;23: 279–91.

    Article  Google Scholar 

  93. Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther. 1999;24:249–57.

    Article  CAS  PubMed  Google Scholar 

  94. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764–71.

    Article  CAS  PubMed  Google Scholar 

  95. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother. 1997;41:1944–8.

    CAS  PubMed  Google Scholar 

  96. Villani R, Regazzi MB, Maserati R, Viale P, Alberici F, Giacchino R. Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients. Arzneimittelforschung. 1996;46:445–9.

    CAS  PubMed  Google Scholar 

  97. Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother. 2006;50:3418–23.

    Article  CAS  PubMed  Google Scholar 

  98. Leenders C, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11:1463–71.

    Article  CAS  PubMed  Google Scholar 

  99. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model. Ophthalmic Res. 2004;36:172–6.

    Article  CAS  PubMed  Google Scholar 

  100. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother. 2002;46:3719–23.

    Article  CAS  PubMed  Google Scholar 

  101. Kretschmar M, Nichterlein T, Hannak D, Hof H. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Arzneimittelforschung. 1996;46:711–5.

    CAS  PubMed  Google Scholar 

  102. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta AL Amph/ ABLC Collaborative Study Group. a randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31:1155–63.

    Article  CAS  PubMed  Google Scholar 

  103. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997;24:635–42.

    Article  CAS  PubMed  Google Scholar 

  104. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296–302.

    Article  CAS  PubMed  Google Scholar 

  105. Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy. 1998;18:1053–61.

    CAS  PubMed  Google Scholar 

  106. Collazos J, Martinez E, Mayo J, Ibarra S. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management. Clin Infect Dis. 2001;33:E75–82.

    Article  CAS  PubMed  Google Scholar 

  107. Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis. 2003;36:1213–20.

    Article  CAS  PubMed  Google Scholar 

  108. McDonnell TJ, Chang SW, Westcott JY, Voelkel NF. Role of oxidants, eicosanoids, and neutrophils in amphotericin B lung injury in rats. J Appl Physiol. 1988;65:2195–206.

    CAS  PubMed  Google Scholar 

  109. Hardie WD, Wheeler AP, Wright PW, Swindell BB, Bernard GR. Effect of cyclooxygenase inhibition on amphotericin B-induced lung injury in awake sheep. J Infect Dis. 1992;166:134–8.

    CAS  PubMed  Google Scholar 

  110. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359–66.

    Article  CAS  PubMed  Google Scholar 

  111. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22:329–30.

    Google Scholar 

  112. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105–9.

    CAS  PubMed  Google Scholar 

  113. Rex JH, Walsh TJ. Editorial response: estimating the true cost of amphotericin B. Clin Infect Dis. 1999;29:1408–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schools of Pharmacy & Medicine, University of Mississippi Medical Center, Jackson, MS, USA

    John D. Cleary

Authors
  1. Stanley W. Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Cleary
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. David Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John D. Cleary .

Editor information

Editors and Affiliations

  1. Veterans Affairs Ann Arbor Healthcare, Professor of Internal Medicine, University of Michigan Medical School, 2215 Fuller Road, Ann Arbor, 48105, Michigan, USA

    Carol A. Kauffman

  2. Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Blvd., Birmingham, 35294, Alabama, USA

    Peter G. Pappas

  3. Division of Infectious Diseases, Wayne State University School of Medicin, 3990 John R Street, Detroit, 48201, Michigan, USA

    Jack D. Sobel

  4. School of Medicine, Professor Emeritus of Medicine, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, 35294, Alabama, USA

    William E. Dismukes

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chapman, S.W., Cleary, J.D., Rogers, P.D. (2011). Amphotericin B. In: Kauffman, C., Pappas, P., Sobel, J., Dismukes, W. (eds) Essentials of Clinical Mycology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6640-7_3

Download citation

Publish with us

Policies and ethics

Search

Navigation